Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA’s Missed User Fee Goals Spiked In 2023 – And Not Just Because Of COVID-19

Jan 16 2024

• By Bridget Silverman

darts — • Source: Shutterstock

Related Content

Closed-Loop Inspections? Strict COVID Zero Policy Delays US FDA’s China Field Trips

May 26 2022

Sarepta's Eteplirsen Approved After Contentious Internal FDA Debate

Sep 20 2016

Few, But Fast And On Time: 2010 Saw Low NMEs, But Almost All Were First-Cycle Approvals And FDA Met Most User Fees

Jan 01 2011

Real-Time Oncology Review Speeds Supplements At US FDA, But Gives Modest Benefit For Novel Agents

Dec 20 2023

End Of US FDA’s Very Fast Reviews? 2022 Novel Approvals Stayed Close To PDUFA Timeframes

Jan 31 2023

Keeping Track: Return & Renewal At US FDA

Sep 23 2023

A 3-Month Delay For A Better Label: US FDA User Fee Goal Extensions Are Usually Good News

Aug 29 2023

Elevidys’ Age-Restricted Indication Not Negotiable, CBER’s Peter Marks Told Sarepta

Aug 08 2023

Related Companies

Sarepta Therapeutics, Inc.

Evive Biotech

Acrotech Biopharma LLC

WuXi Biologics

Amicus Therapeutics, Inc.

Junshi Biosciences/Immorna Joint Venture

Coherus Oncology, Inc.

BeOne Medicines Ltd.

Novartis AG

Akeso Inc.

Sino Biopharmaceutical Limited

Pfizer Inc.

Additional Topics

United States Drug Review Drug Approval Standards Regulation Pink Sheet Perspectives US FDA Performance Tracker BioPharmaceutical

More from Pink Sheet Perspectives

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window